Prestige Consumer Healthcare (NYSE:PBH) Downgraded by Sidoti to “Neutral”

Sidoti downgraded shares of Prestige Consumer Healthcare (NYSE:PBH) from a buy rating to a neutral rating in a research note issued to investors on Monday, Marketbeat.com reports. The brokerage currently has $90.00 price target on the stock.

Other equities analysts have also recently issued research reports about the company. DA Davidson restated a “buy” rating and set a $95.00 price target on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Jefferies Financial Group restated a “hold” rating and set a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $85.25.

Prestige Consumer Healthcare Stock Down 1.2 %

NYSE PBH opened at $83.28 on Monday. The stock’s 50-day moving average price is $77.01 and its 200-day moving average price is $72.05. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare has a 52 week low of $57.95 and a 52 week high of $86.36. The company has a market capitalization of $4.11 billion, a P/E ratio of 20.26, a price-to-earnings-growth ratio of 2.37 and a beta of 0.49.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.09. The company had revenue of $283.79 million for the quarter, compared to the consensus estimate of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The firm’s quarterly revenue was down .9% on a year-over-year basis. During the same quarter last year, the company earned $1.07 EPS. On average, equities research analysts predict that Prestige Consumer Healthcare will post 4.44 earnings per share for the current year.

Insider Transactions at Prestige Consumer Healthcare

In related news, CEO Ronald M. Lombardi sold 10,875 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the transaction, the chief executive officer now directly owns 320,952 shares of the company’s stock, valued at $26,510,635.20. This represents a 3.28 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider William P’pool sold 8,987 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the transaction, the insider now directly owns 20,058 shares in the company, valued at $1,641,747.30. This represents a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 38,810 shares of company stock valued at $3,187,300. Corporate insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in PBH. Quest Partners LLC grew its stake in Prestige Consumer Healthcare by 2,826.7% during the 2nd quarter. Quest Partners LLC now owns 439 shares of the company’s stock valued at $30,000 after purchasing an additional 424 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Prestige Consumer Healthcare by 562.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after buying an additional 433 shares during the last quarter. Gladius Capital Management LP purchased a new stake in shares of Prestige Consumer Healthcare in the second quarter worth about $35,000. ORG Partners LLC purchased a new stake in shares of Prestige Consumer Healthcare in the second quarter worth about $39,000. Finally, nVerses Capital LLC boosted its stake in shares of Prestige Consumer Healthcare by 200.0% in the third quarter. nVerses Capital LLC now owns 600 shares of the company’s stock worth $43,000 after buying an additional 400 shares during the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.